Do analysts recommend BNR or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 6,656.76%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer BNR or BTAI?

In the previous week, BioXcel Therapeutics had 6 more articles in the media than Burning Rock Biotech. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for Burning Rock Biotech. BioXcel Therapeutics' average media sentiment score of 0.96 beat Burning Rock Biotech's score of 0.63 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BTAI or DTSQ?

BioXcel Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 6,656.76%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, BTAI or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than BioXcel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioXcel Therapeutics $640K 7.96 -$69.90M -$3.79 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is BTAI or DTSQ more profitable?

DT Cloud Star Acquisition has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -9,549.87% N/A -185.82% DT Cloud Star Acquisition N/A N/A N/A

Does the media favor BTAI or DTSQ?

In the previous week, BioXcel Therapeutics had 6 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat BioXcel Therapeutics' score of 0.96 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or BTAI more profitable?

Oncobiologics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% BioXcel Therapeutics -9,549.87% N/A -185.82%

Does the media prefer OTLK or BTAI?

In the previous week, BioXcel Therapeutics had 6 more articles in the media than Oncobiologics. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for Oncobiologics. BioXcel Therapeutics' average media sentiment score of 0.96 beat Oncobiologics' score of 0.62 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KLRS or BTAI?

In the previous week, BioXcel Therapeutics had 6 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.96 beat BioXcel Therapeutics' score of 0.96 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PCSC or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 6,656.76%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Perceptive Capital Solutions. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perceptive Capital Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

BioXcel Therapeutics (BTAI) Competitors

$0.16 -0.02 (-10.25%)

As of 04:00 PM Eastern

Compare

BTAI vs. BNR, DTSQ, OTLK, KLRS, and PCSC

Should you buy BioXcel Therapeutics stock or one of its competitors? BioXcel Therapeutics's main competitors and comparable companies include Burning Rock Biotech (BNR), DT Cloud Star Acquisition (DTSQ), Oncobiologics (OTLK), Kalaris Therapeutics (KLRS), and Perceptive Capital Solutions (PCSC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioXcel Therapeutics compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, BioXcel Therapeutics had 6 more articles in the media than Burning Rock Biotech. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for Burning Rock Biotech. BioXcel Therapeutics' average media sentiment score of 0.96 beat Burning Rock Biotech's score of 0.63 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioXcel Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 6,656.76%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Burning Rock Biotech has higher revenue and earnings than BioXcel Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.29	-$7.92M	-$0.82	N/A
BioXcel Therapeutics	$640K	7.96	-$69.90M	-$3.79	N/A

Burning Rock Biotech has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Burning Rock Biotech has a net margin of -11.57% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

Summary

BioXcel Therapeutics beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to DT Cloud Star Acquisition?

BioXcel Therapeutics (NASDAQ:BTAI) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

30.7% of BioXcel Therapeutics shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DT Cloud Star Acquisition has lower revenue, but higher earnings than BioXcel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	7.96	-$69.90M	-$3.79	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

BioXcel Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 6,656.76%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

DT Cloud Star Acquisition has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%
DT Cloud Star Acquisition	N/A	N/A	N/A

In the previous week, BioXcel Therapeutics had 6 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat BioXcel Therapeutics' score of 0.96 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioXcel Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioXcel Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Summary

BioXcel Therapeutics beats DT Cloud Star Acquisition on 7 of the 11 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Oncobiologics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oncobiologics presently has a consensus price target of $5.20, indicating a potential upside of 720.97%. BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 6,656.76%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Oncobiologics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

In the previous week, BioXcel Therapeutics had 6 more articles in the media than Oncobiologics. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for Oncobiologics. BioXcel Therapeutics' average media sentiment score of 0.96 beat Oncobiologics' score of 0.62 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioXcel Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics has higher revenue and earnings than BioXcel Therapeutics. Oncobiologics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	114.22	-$62.42M	-$0.77	N/A
BioXcel Therapeutics	$640K	7.96	-$69.90M	-$3.79	N/A

Summary

BioXcel Therapeutics beats Oncobiologics on 8 of the 14 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Kalaris Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kalaris Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 364.11%. BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 6,656.76%. Given BioXcel Therapeutics' higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, BioXcel Therapeutics had 6 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 3 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.96 beat BioXcel Therapeutics' score of 0.96 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioXcel Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

Kalaris Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
BioXcel Therapeutics	$640K	7.96	-$69.90M	-$3.79	N/A

Summary

Kalaris Therapeutics beats BioXcel Therapeutics on 10 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Perceptive Capital Solutions?

Perceptive Capital Solutions (NASDAQ:PCSC) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Perceptive Capital Solutions has higher earnings, but lower revenue than BioXcel Therapeutics. Perceptive Capital Solutions is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perceptive Capital Solutions	N/A	N/A	$840K	-$0.06	N/A
BioXcel Therapeutics	$640K	7.96	-$69.90M	-$3.79	N/A

30.7% of BioXcel Therapeutics shares are owned by institutional investors. 22.1% of Perceptive Capital Solutions shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 6,656.76%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Perceptive Capital Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perceptive Capital Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, BioXcel Therapeutics had 9 more articles in the media than Perceptive Capital Solutions. MarketBeat recorded 9 mentions for BioXcel Therapeutics and 0 mentions for Perceptive Capital Solutions. BioXcel Therapeutics' average media sentiment score of 0.96 beat Perceptive Capital Solutions' score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Perceptive Capital Solutions	Neutral
BioXcel Therapeutics	Positive

Perceptive Capital Solutions has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Perceptive Capital Solutions has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Perceptive Capital Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perceptive Capital Solutions	N/A	-2.70%	-0.84%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

Summary

BioXcel Therapeutics beats Perceptive Capital Solutions on 9 of the 15 factors compared between the two stocks.

Get BioXcel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTAI vs. The Competition

Export

Metric	BioXcel Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.68M	$3.93B	$7.20B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.04	11.63	272.59	25.48
Price / Sales	7.96	1,342.27	624.07	92.57
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	-0.04	16.81	11.05	6.34
Net Income	-$69.90M	-$22.71M	$3.47B	$349.45M
7 Day Performance	-78.60%	2.89%	1.28%	-0.10%
1 Month Performance	-79.85%	13.06%	8.29%	4.36%
1 Year Performance	-95.98%	55.07%	24.29%	14.91%

BioXcel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTAI BioXcel Therapeutics	2.4315 of 5 stars	$0.16 -10.3%	$11.00 +6,656.8%	-95.5%	$5.68M	$640K	N/A	90	News Coverage Gap Down High Trading Volume
BNR Burning Rock Biotech	0.7653 of 5 stars	$9.70 +4.9%	N/A	+19.1%	$102.03M	$514.43M	N/A	1,390	Upcoming Earnings
DTSQ DT Cloud Star Acquisition	1.7152 of 5 stars	$11.40 +0.9%	N/A	+8.5%	$101.47M	N/A	N/A	N/A	Positive News Short Interest Decrease
OTLK Oncobiologics	3.6379 of 5 stars	$0.68 +0.6%	$4.65 +583.4%	-24.2%	$101.10M	-$1.16M	N/A	20	Gap Down
KLRS Kalaris Therapeutics	2.6859 of 5 stars	$4.10 -0.5%	$18.75 +357.3%	-1.2%	$97.60M	N/A	N/A	110	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTAI) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. BNR, DTSQ, OTLK, KLRS, and PCSC

How does BioXcel Therapeutics compare to Burning Rock Biotech?

Summary

How does BioXcel Therapeutics compare to DT Cloud Star Acquisition?

Summary

How does BioXcel Therapeutics compare to Oncobiologics?

Summary

How does BioXcel Therapeutics compare to Kalaris Therapeutics?

Summary

How does BioXcel Therapeutics compare to Perceptive Capital Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. BNR, DTSQ, OTLK, KLRS, and PCSC

How does BioXcel Therapeutics compare to Burning Rock Biotech?

Does the media prefer BNR or BTAI?

Do analysts recommend BNR or BTAI?

Do insiders & institutionals believe in BNR or BTAI?

Which has better earnings and valuation, BNR or BTAI?

Which has more volatility and risk, BNR or BTAI?

Is BNR or BTAI more profitable?

Summary

How does BioXcel Therapeutics compare to DT Cloud Star Acquisition?

Do institutionals & insiders have more ownership in BTAI or DTSQ?

Which has stronger valuation and earnings, BTAI or DTSQ?

Do analysts rate BTAI or DTSQ?

Is BTAI or DTSQ more profitable?

Does the media favor BTAI or DTSQ?

Which has more volatility and risk, BTAI or DTSQ?

Summary

How does BioXcel Therapeutics compare to Oncobiologics?

Which has more volatility & risk, OTLK or BTAI?

Do institutionals & insiders believe in OTLK or BTAI?

Do analysts prefer OTLK or BTAI?

Is OTLK or BTAI more profitable?

Does the media prefer OTLK or BTAI?

Which has preferable valuation & earnings, OTLK or BTAI?

Summary

How does BioXcel Therapeutics compare to Kalaris Therapeutics?

Which has more volatility and risk, KLRS or BTAI?

Do insiders and institutionals hold more shares of KLRS or BTAI?

Do analysts rate KLRS or BTAI?

Does the media refer more to KLRS or BTAI?

Is KLRS or BTAI more profitable?

Which has higher valuation & earnings, KLRS or BTAI?

Summary

How does BioXcel Therapeutics compare to Perceptive Capital Solutions?

Which has stronger earnings and valuation, PCSC or BTAI?

Do institutionals & insiders hold more shares of PCSC or BTAI?

Do analysts prefer PCSC or BTAI?

Does the media refer more to PCSC or BTAI?

Which has more volatility & risk, PCSC or BTAI?

Is PCSC or BTAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools